Key facts
- SingleTimeMicroneedles’s last known valuation is $3.5M (Jan 2024).
- It has raised $2.5M across 1 recorded rounds; the latest was Seed Round ($350K) in Jan 2024.
- Notable investors include gBETA, Gazelle Capital, Health Advance Partners, Marty Isaac, Peachscore + Gust Accelerator Program — 12 tracked in total.
- SingleTimeMicroneedles has filed 1 Form D with the SEC, most recently Jan 2024 ($350K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for SingleTimeMicroneedles
Funding rounds
1 roundsAbout SingleTimeMicroneedles
Developer of a multi-dose, microneedle and formulation platform designed to deliver drugs, vaccines and supplements to both animals and humans. The company's platform offers a thermally stable multi-dose microneedle patch that painlessly embeds micron-sized needles into the skin, enabling human and veterinary health providers to deliver treatments immediately, consistently over time or in separate doses with minimal risk of infection.
- Sector
- Healthcare
- HQ
- Storrs., CT, United States
- Founded
- 2022
- Employees
- 9
- Website
- stmpatch.com/
- Ownership
- Privately Held (backing)
SingleTimeMicroneedles doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SingleTimeMicroneedles shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SingleTimeMicroneedles in its N-PORT filings yet. We sweep new filings monthly.